what is retatrutide called How Does Work? Triple Agonist Explained Retatrutide for weight loss: how

At Soza Clinic in Richardson, TX, we recognize and respect the nuances of every individuals health journey

What's New: TRIUMPH-1 Announced (May 21, 2026) Results announced: May 21, 2026 Eli Lilly press release Trial status: Complete all primary and key secondary endpoints met Key result: 28.3% average weight loss at 80 weeks (12mg dose, N=2,339) NDA impact: Eli Lilly now has the primary efficacy dataset required for Q4 2026 NDA filing Next trial to watch: TRIUMPH-2 (diabetes) expected Q3Q4 2026 Introduction On May 21, 2026, Eli Lilly announced the topline results of TRIUMPH-1 the pivotal Phase 3 trial that determines whether retatrutide will receive FDA approval for obesity treatment

Your provider should consider personal and family bleeding history

Are the safety profiles the same

Our treatments do more than just whiten the skins surface